Foghorn Therapeutics (FHTX) Net Cash Flow Growth (1y) (2020 - 2026)
Foghorn Therapeutics (FHTX) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 53.46% |
| 10 | Foghorn Therapeutics | 351.87 Mn | 262.96 Mn | - | 21.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.81% |
| Dec 31, 2025 | -280.31% |
| Sep 30, 2025 | 120.63% |
| Jun 30, 2025 | -78.07% |
| Mar 31, 2025 | 614.50% |
| Dec 31, 2024 | -122.17% |
| Sep 30, 2024 | -744.84% |
| Jun 30, 2024 | 745.28% |
| Mar 31, 2024 | 31.15% |
| Dec 31, 2023 | 128.32% |
| Sep 30, 2023 | -52.26% |
| Jun 30, 2023 | 104.63% |
| Mar 31, 2023 | -101.40% |
| Dec 31, 2022 | -181.80% |
| Sep 30, 2022 | 139.21% |
| Jun 30, 2022 | -359.62% |
| Mar 31, 2022 | 527.04% |
| Dec 31, 2021 | 145.52% |
| Sep 30, 2021 | -276.91% |
| Jun 30, 2021 | 77.29% |